Anlotinib plus immunotherapy for advanced endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two investigational drugs—anlotinib (a capsule that blocks blood supply to tumors) and TQB2450 (an immunotherapy that helps your immune system attack cancer cells)—for people with recurrent or metastatic endometrial cancer that has not responded to previous platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or recurrent endometrial cancer that has come back after 1–2 rounds of platinum-based chemotherapy
- Your tumor is not MSI-high (genetically unstable) or is microsatellite stable
- You have at least one measurable tumor that can be seen on scans
- You are in fairly good physical shape (able to do daily activities with little help) and are 18 years or older
- You have not used certain anti-angiogenic drugs (like Avastin, Lenvima) or PD-1/PD-L1 immunotherapy before
- You do not have active brain metastases, uncontrolled fluid buildup in the belly or chest, or recent blood clots
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
This trial tests a combination of two medicines (camrelizumab and anlotinib) for endometrial cancer that has spread back or continued and has specific tumor gene changes called MMRd. It may help shrink tumors or control the disease by activating the immune system and blocking cancer growth signals.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This trial tests a combination of the immunotherapy drug tislelizumab (which helps your immune system fight cancer) with standard chemotherapy, given before surgery for advanced endometrial cancer. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy for women with advanced or recurrent endometrial cancer that hasn't been treated yet. It may help shrink or control the cancer.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.